JB/CALL/JOHNSON & JOHNSON/180/0.025/20.12.24 Stock

Warrant

JNJFJB

CH1263884491

Market Closed - Swiss Exchange 11:20:00 2024-05-28 am EDT
0.02 CHF -33.33% Intraday chart for JB/CALL/JOHNSON & JOHNSON/180/0.025/20.12.24
Current month-25.93%
1 month-28.57%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change

Delayed Quote Swiss Exchange

Last update May 28, 2024 at 11:20 am EDT

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying JOHNSON & JOHNSON
Issuer Bank Julius Bär
JNJFJB
ISINCH1263884491
Date issued 2023-06-05
Strike 180 $
Maturity 2024-12-20 (203 Days)
Parity 40 : 1
Emission price 0.18 CHF
Emission volume N/A
Settlement règlement en espèces
Currency CHF

Technical Indicators

Highest since issue 0.31 CHF
Lowest since issue 0.02 CHF
Delta0.09x
Omega 16.37
Premium23.26x
Gearing174.37x
Moneyness 0.8151
Difference Strike 33.14 $
Difference Strike %+18.41%
Spread 0.01 CHF
Spread %41.67%
Theoretical value 0.0190
Implied Volatility 18.50 %
Total Loss Probability 92.60 %
Intrinsic value 0.000000
Present value 0.0190
Break even 180.84 CHF
Theta-0x
Vega0x
Rho0x

Company Profile

Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
Sector
-
More about the company

Ratings for Johnson & Johnson

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Johnson & Johnson

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
146.7 USD
Average target price
171.9 USD
Spread / Average Target
+17.23%
Consensus
  1. Stock Market
  2. Warrants
  3. JNJFJB Warrant